Department of Pharmacology, Government Medical College, Jagdalpur, Chhattisgarh, India.
Indian J Pharmacol. 2011 Feb;43(1):84-6. doi: 10.4103/0253-7613.75680.
Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is widely prescribed as a part of the combination therapy of human immunodeficiency virus (HIV) infection because of its efficacy and good tolerability. Here, we report a case of Stevens-Johnson syndrome (SJS) secondary to nevirapine. The patient had a diffuse, exfoliating exanthema with generalized bullous eruptions that involved the face, trunk and both extremities with elevated hepatic alanine aminotransferase and aspartate aminotransferase enzyme activities. The condition improved with stoppage of nevirapine-based highly active antiretroviral therapy (HAART) regimen, so we attributed this adverse event to nevirapine. A strict vigilance of adverse drug reaction is required in HAART.
奈韦拉平是一种非核苷类逆转录酶抑制剂（NNRTI），由于其疗效好且耐受性良好，被广泛用作人类免疫缺陷病毒（HIV）感染联合治疗的一部分。在这里，我们报告了一例奈韦拉平引起的史蒂文斯-约翰逊综合征（SJS）。患者出现弥漫性、剥脱性发疹，全身大疱性皮疹累及面部、躯干和四肢，伴有肝丙氨酸氨基转移酶和天冬氨酸氨基转移酶活性升高。停用奈韦拉平为基础的高效抗逆转录病毒治疗（HAART）方案后，病情有所改善，因此我们将这一不良事件归因于奈韦拉平。在 HAART 中需要严格监测药物不良反应。
